JP2017520531A - Ｆｃ断片の産生 - Google Patents

Ｆｃ断片の産生 Download PDF

Info

Publication number
JP2017520531A
JP2017520531A JP2016568950A JP2016568950A JP2017520531A JP 2017520531 A JP2017520531 A JP 2017520531A JP 2016568950 A JP2016568950 A JP 2016568950A JP 2016568950 A JP2016568950 A JP 2016568950A JP 2017520531 A JP2017520531 A JP 2017520531A
Authority
JP
Japan
Prior art keywords
fragment
antibody
hydrophobic interaction
transgenic
fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016568950A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017520531A5 (enExample
Inventor
シー マシエロ，ニコラス
シー マシエロ，ニコラス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LFB SA filed Critical LFB SA
Publication of JP2017520531A publication Critical patent/JP2017520531A/ja
Publication of JP2017520531A5 publication Critical patent/JP2017520531A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/30—Partition chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • B01D15/426—Specific type of solvent
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/04—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22002—Papain (3.4.22.2)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/26—Further operations combined with membrane separation processes
    • B01D2311/2626—Absorption or adsorption
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Water Supply & Treatment (AREA)
  • Biotechnology (AREA)
  • Environmental Sciences (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016568950A 2014-06-02 2015-06-02 Ｆｃ断片の産生 Pending JP2017520531A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462006584P 2014-06-02 2014-06-02
US62/006,584 2014-06-02
PCT/IB2015/001643 WO2015186004A2 (en) 2014-06-02 2015-06-02 Production of fc fragments

Publications (2)

Publication Number Publication Date
JP2017520531A true JP2017520531A (ja) 2017-07-27
JP2017520531A5 JP2017520531A5 (enExample) 2018-07-12

Family

ID=54337822

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016568950A Pending JP2017520531A (ja) 2014-06-02 2015-06-02 Ｆｃ断片の産生

Country Status (12)

Country Link
US (1) US20170129966A1 (enExample)
EP (1) EP3149030A2 (enExample)
JP (1) JP2017520531A (enExample)
KR (1) KR20170040132A (enExample)
CN (1) CN106573973A (enExample)
AR (1) AR100716A1 (enExample)
AU (1) AU2015270152A1 (enExample)
BR (1) BR112016028182A2 (enExample)
CA (1) CA2950241A1 (enExample)
IL (1) IL249274A0 (enExample)
MX (1) MX2016015893A (enExample)
WO (1) WO2015186004A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021508444A (ja) * 2017-12-15 2021-03-11 ラボラトワール フランセ デュ フラクシオヌマン エ デ ビオテクノロジＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ Ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ Ｅｔ Ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ ＦｃＲｎに対する増大した親和性および少なくとも１つのＦｃフラグメント受容体に対する増大した親和性を有するＦｃフラグメントを伴う変異体

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011350895B2 (en) 2010-12-30 2015-05-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Glycols as pathogen inactivating agents
EP2956003A2 (en) 2013-02-13 2015-12-23 Laboratoire Français du Fractionnement et des Biotechnologies Proteins with modified glycosylation and methods of production thereof
KR20160002713A (ko) 2013-02-13 2016-01-08 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 고도로 갈락토실화된 항-tnf-알파 항체 및 이의 용도
CA2916566A1 (fr) 2013-07-05 2015-01-08 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Matrice de chromatographie d'affinite
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
CN111344301A (zh) * 2017-11-14 2020-06-26 生物资源公司 抗体纯化
WO2019116096A1 (en) * 2017-12-15 2019-06-20 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Production of fc fragments
US11155575B2 (en) 2018-03-21 2021-10-26 Waters Technologies Corporation Non-antibody high-affinity-based sample preparation, sorbent, devices and methods
CN110669134A (zh) * 2019-10-15 2020-01-10 广东菲鹏生物有限公司 IgM-FC片段、IgM-FC抗体及制备方法和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09506779A (ja) * 1993-12-20 1997-07-08 ゲンザイム・トランスゲニックス・コーポレイション 乳汁中における抗体の形質転換的な産生
JP2000510701A (ja) * 1996-05-13 2000-08-22 ジェンザイム トランスジェニックス コーポレイション 生物学的に活性なペプチドのミルクからの精製
JP2008543868A (ja) * 2005-06-17 2008-12-04 ワイス Ｆｃ領域含有タンパク質を精製する方法
JP2009532477A (ja) * 2006-04-05 2009-09-10 ザ ロックフェラー ユニバーシティ 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
JP2010529999A (ja) * 2007-06-14 2010-09-02 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗体製剤
WO2013021279A2 (en) * 2011-08-10 2013-02-14 Lfb Biotechnologies Highly galactosylated antibodies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0690452A3 (en) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Electrically erasable memory and method of erasure
US5843705A (en) 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
US5945577A (en) 1997-01-10 1999-08-31 University Of Massachusetts As Represented By Its Amherst Campus Cloning using donor nuclei from proliferating somatic cells
CN101687933B (zh) 2007-05-30 2015-11-25 浦项工科大学校产学协力团 免疫球蛋白融合蛋白
EP2599494A1 (en) 2010-01-11 2013-06-05 Healor Ltd. PKC inhibitors for the treatment of inflammatory disease or disorder
GB201115665D0 (en) 2011-09-09 2011-10-26 Univ Leuven Kath Autoimmune and inflammatory disorder therapy

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09506779A (ja) * 1993-12-20 1997-07-08 ゲンザイム・トランスゲニックス・コーポレイション 乳汁中における抗体の形質転換的な産生
JP2000510701A (ja) * 1996-05-13 2000-08-22 ジェンザイム トランスジェニックス コーポレイション 生物学的に活性なペプチドのミルクからの精製
JP2008543868A (ja) * 2005-06-17 2008-12-04 ワイス Ｆｃ領域含有タンパク質を精製する方法
JP2009532477A (ja) * 2006-04-05 2009-09-10 ザ ロックフェラー ユニバーシティ 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
JP2010529999A (ja) * 2007-06-14 2010-09-02 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗体製剤
WO2013021279A2 (en) * 2011-08-10 2013-02-14 Lfb Biotechnologies Highly galactosylated antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J CHROMATOGR A, 2008, VOL.1214, P.81-89, JPN6019013847, ISSN: 0004149490 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021508444A (ja) * 2017-12-15 2021-03-11 ラボラトワール フランセ デュ フラクシオヌマン エ デ ビオテクノロジＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ Ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ Ｅｔ Ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ ＦｃＲｎに対する増大した親和性および少なくとも１つのＦｃフラグメント受容体に対する増大した親和性を有するＦｃフラグメントを伴う変異体
JP2023134604A (ja) * 2017-12-15 2023-09-27 ラボラトワール フランセ デュ フラクシオヌマン エ デ ビオテクノロジ ＦｃＲｎに対する増大した親和性および少なくとも１つのＦｃフラグメント受容体に対する増大した親和性を有するＦｃフラグメントを伴う変異体
JP7897688B2 (ja) 2017-12-15 2026-07-30 ラボラトワール フランセ デュ フラクシオヌマン エ デ ビオテクノロジ ＦｃＲｎに対する増大した親和性および少なくとも１つのＦｃフラグメント受容体に対する増大した親和性を有するＦｃフラグメントを伴う変異体

Also Published As

Publication number Publication date
MX2016015893A (es) 2017-03-20
EP3149030A2 (en) 2017-04-05
WO2015186004A3 (en) 2016-05-12
AU2015270152A1 (en) 2016-12-08
IL249274A0 (en) 2017-02-28
AR100716A1 (es) 2016-10-26
KR20170040132A (ko) 2017-04-12
CN106573973A (zh) 2017-04-19
CA2950241A1 (en) 2015-12-10
WO2015186004A2 (en) 2015-12-10
US20170129966A1 (en) 2017-05-11
BR112016028182A2 (pt) 2018-02-20

Similar Documents

Publication Publication Date Title
US20170129966A1 (en) Production of fc fragments
CN112400022B (zh) 具有人源化免疫球蛋白基因座的经遗传修饰的非人动物
ES2755181T3 (es) Anticuerpos anti-TNF-alfa altamente galactosilados y usos de los mismos
JP5184374B2 (ja) 対立遺伝子排除
JP2023165683A (ja) 限定された免疫グロブリン重鎖遺伝子座を有するヒト化非ヒト動物
JP5866127B2 (ja) Ａｄａｍ６マウス
JP2022048158A (ja) 限定された免疫グロブリン重鎖のマウス
CN109906030B (zh) 用于产生仅重链抗体的经基因修饰的非人动物和方法
EP2956484B1 (en) Cetuximab with modified glycosylation and uses thereof
WO2021244522A1 (en) Genetically modified non-human animals with common light chain immunoglobulin locus
JP2006507839A (ja) 乳中に安定して産生される改変抗体およびその製造方法
JP2016533768A (ja) ヒスチジン操作軽鎖抗体およびそれを生成するための遺伝子改変非ヒト動物
JP2020125286A (ja) 高ガラクトシル化抗ｈｅｒ２抗体およびその使用
JP2022507307A (ja) ヒト血清アルブミンに結合する単一ドメイン抗体
JP2018515073A (ja) Ｆｃ融合タンパク質のトランスジェニック産生
JP2014511688A (ja) Ｈｍｇｂ１に特異的なモノクローナル抗体
WO2019116096A1 (en) Production of fc fragments
RU2841160C1 (ru) Генетически модифицированные животные, отличные от человека, содержащие локус общей легкой цепи иммуноглобулина
WO2020053661A1 (en) Methods of purifying antibodies from the milk of transgenic non-human mammals comprising the use of chitosan
HK1124363B (en) Transgenic mammal carrying ganp gene transferred thereinto and utilization thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180531

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190417

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190717

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191113